Ronald Acuña Jr. activated by Braves after second hamstring IL stint of 2026

What happened

The Atlanta Braves announced they have reinstated Ronald Acuña Jr. from the 10-day injured list, ending his second hamstring-related absence of the 2026 season. Buster Olney of ESPN reported the move shortly before the club's official announcement. To open a spot on the 26-man roster, outfielder Brewer Hicklen was optioned to Triple-A Gwinnett.

Acuña had been sidelined since early June with a hamstring strain — his second such trip to the injured list this year. The first stint cost him just over two weeks, but renewed symptoms emerged only three weeks after he was activated from that initial absence. Per MLB Trade Rumors, Atlanta took a more cautious and measured approach with this second stint before bringing him back.

Why it matters

The Braves are heading into a three-game road series at Citi Field against the New York Mets, and Acuña's return lands at a moment when the lineup could use its most dynamic presence. Atlanta enters the week having dropped its most recent game — a one-game losing streak, which is the kind of streak that sounds almost quaint when you're sitting at 94-68 — but the broader picture is a club firmly in control of the NL East.

The hamstring history is the part worth watching carefully. Two strains in the same season, with a recurrence arriving just three weeks after the first activation, is the kind of pattern that tends to make training staffs cautious and beat writers nervous. The club's decision to extend the second IL stint rather than rush Acuña back suggests Atlanta is prioritizing durability over a few extra games in July. Whether that patience pays off is the question that will follow him through the rest of the regular season.

Hicklen's optioning is the mechanical footnote that makes the roster math work. Under general league rules, a player must be on the 40-man roster to occupy an active roster spot, and the 26-man limit through August 31 means every activation requires a corresponding move. Hicklen retains options, so the transaction is straightforward — a temporary reshuffling rather than a roster crisis.

The numbers

When Acuña has been available this season, he has not been the version that set the sport's expectations at a nearly impossible altitude — but he has been, by any reasonable measure, a well-above-average offensive player. Per MLB Trade Rumors, he has slashed .251/.373/.421 with a 121 wRC+, meaning he has produced roughly that many percentage points above a league-average hitter after adjusting for park and environment.

The counting numbers: seven home runs, 10 doubles, a triple, and 15 stolen bases in 22 attempts. The stolen base line is worth a moment's pause. Fifteen steals in 22 tries, while managing a hamstring that has twice sent him to the injured list, is either a testament to his athleticism or a detail that will make the training staff's eye twitch slightly every time he breaks for second. Probably both.

The .373 on-base percentage is the number that most clearly signals the plate discipline is intact even when the power hasn't fully arrived. A hitter who gets on base at that clip, with that kind of speed, is a problem for opposing pitchers regardless of whether the home run total is tracking toward his previous peaks.

Where the club stands

Atlanta is 94-68 (.580) and leading the NL East, arriving at Citi Field on a one-game losing streak. The Braves open the series Monday with Martín Pérez scheduled against Zac Thornton, then send Chris Sale out Tuesday against Christian Scott, and close Wednesday with AJ Smith-Shawver facing Sean Manaea.

A road series against a division rival is precisely the kind of moment a club wants its best players available. The timing of Acuña's reinstatement — arriving just as this series opens — is either very good planning or very good fortune, and in baseball the line between those two things is often thinner than it appears.

Sale's Tuesday start is its own subplot. The veteran left-hander against a Mets lineup at Citi Field is a marquee matchup regardless of what else is happening around it, and Smith-Shawver closing out the series on Wednesday gives Atlanta a look at one of its younger arms in a meaningful spot.

What we don't know yet

The central uncertainty here is durability. Per MLB Trade Rumors, Acuña experienced renewed symptoms just three weeks after his first activation, which is what prompted the more extended second absence. The club will now hope, as the report puts it, that the injury is completely in the rearview mirror — but that hope is not a medical clearance, and the hamstring's recent history means every sprint and stolen base attempt will carry a small asterisk until he strings together a longer run of healthy games.

It is also worth noting that Acuña's 2026 production, while above average, has not matched what the sport has come to expect from him at full health. Whether the hamstring issues are connected to that gap, or whether the two things are simply coinciding, is not something the available reporting addresses. MLB Trade Rumors does not make that causal claim, and neither will this desk.

Hicklen's path back to the active roster is similarly unresolved. He was optioned rather than designated for assignment, which means he remains on the 40-man roster and is available to be recalled. When or whether that happens depends on how the roster shapes up over the coming weeks.

What to watch

The most immediate question is how Atlanta manages Acuña's workload as he returns from his second hamstring stint. A player coming off a recurrence, with a history of renewed symptoms arriving quickly after the first activation, is a candidate for careful handling — limited starts, rest days built into the schedule, perhaps some restraint on the basepaths. Whether the Braves take that approach or turn him loose immediately is worth monitoring from the first game he appears in.

The stolen base number is the specific thing to watch. Fifteen attempts in 22 tries is an aggressive pace for a player managing a hamstring, and how freely Acuña runs in the coming weeks will say something about how confident the club is in his recovery.

The Mets series itself is the immediate backdrop. Atlanta is leading the NL East at 94-68 (.580), but a road series against a division rival is not the place to be shorthanded in the outfield. Acuña's presence changes the calculus of that lineup in ways that go beyond any single number — the threat of his speed alone affects how pitchers work, how defenses align, and how the middle of the order gets pitched.

And then there is the longer arc: a player of Acuña's caliber, returning from a second hamstring injury in the same season, navigating the final stretch of a pennant race. The Braves have built enough of a lead that they can afford some caution. Whether they exercise it, or whether Acuña simply takes the field and makes the question moot, is the story to follow.